Compare · MRNA vs PMCB
MRNA vs PMCB
Side-by-side comparison of Moderna Inc. (MRNA) and PharmaCyte Biotech Inc. (PMCB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and PMCB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.82B, about 2504.8x PMCB ($7.5M).
- Over the past year, MRNA is up 68.5% and PMCB is down 36.4% - MRNA leads by 105.0 points.
- MRNA has hit the wire 12 times in the past 4 weeks while PMCB has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 1 for PMCB).
- Company
- Moderna Inc.
- PharmaCyte Biotech Inc.
- Price
- $47.41-8.12%
- $0.67-8.01%
- Market cap
- $18.82B
- $7.5M
- 1M return
- -2.76%
- -9.21%
- 1Y return
- +68.54%
- -36.45%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 1
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
PharmaCyte Biotech Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
Latest MRNA
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)
- President Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)
- Director Afeyan Noubar exercised 9,263 shares at a strike of $19.15 and sold $433,879 worth of shares (9,263 units at $46.84) (SEC Form 4)
Latest PMCB
- SEC Form 4 filed by Walker Wayne Remell
- SEC Form 4 filed by Weinstein Robert
- SEC Form 4 filed by Schechter Jonathan
- SEC Form 4 filed by Abecassis Michael M
- PharmaCyte Biotech Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by PharmaCyte Biotech Inc.
- SEC Form DEF 14A filed by PharmaCyte Biotech Inc.
- SEC Form PRE 14A filed by PharmaCyte Biotech Inc.
- CEO and President Silverman Joshua bought $80,476 worth of shares (100,000 units at $0.80), increasing direct ownership by 32% to 416,250 units (SEC Form 4)
- Director Schechter Jonathan bought $48,232 worth of shares (60,000 units at $0.80), increasing direct ownership by 45% to 192,500 units (SEC Form 4)